Efficacy and safety of probiotics in Parkinson's constipation: A systematic review and meta-analysis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.

1. Gut-brain axis dysfunction in Parkinson's disease: a meta-analysis of microbiome dysbiosis and intestinal barrier markers.Frontiers in medicine · 2026
   Pooled it
2. Efficacy and safety of GLP-1 agonists in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.Naunyn-Schmiedeberg's archives of pharmacology · 2025
   Pooled it
3. Probiotics in epilepsy treatment: a meta-analysis of efficacy and safety.Frontiers in microbiology · 2025
   Pooled it
4. Randomized controlled trial evaluating synbiotic supplementation as an adjuvant therapy in the treatment of Parkinson's disease.Inflammopharmacology · 2025
   Trial
5. Synbiotic supplementation may globally improve non-motor symptoms in patients with stable Parkinson's disease: results from an open label single-arm study.Scientific reports · 2024
   Trial
6. Preventive Attenuation of MPTP-Induced Parkinson's Disease-like Abnormalities byFoods (Basel, Switzerland) · 2026
   Article
7. "Unfolding Parkinson's Disease Through the Microbiome-Gut-Brain Axis".Journal of molecular neuroscience : MN · 2026
   Review
8. Elevated Lactobacillus salivarius and genus Akkermansia in fecal samples of Taiwanese patients with parkinson's disease and diabetes mellitus.Scientific reports · 2025
   Article
9. Short-Chain Fatty Acids as a Therapeutic Strategy in Parkinson's Disease: Implications for Neurodegeneration.Cellular and molecular neurobiology · 2025
   Review
10. Gut Microbiome as a Source of Probiotic Drugs for Parkinson's Disease.International journal of molecular sciences · 2025
    Review
11. The role of microbiota dysbiosis in Parkinson's disease: Pathophysiology and therapeutic opportunities.Engineering microbiology · 2025
    Review
12. The effect of probiotic supplementation on constipation in patients with Parkinson's disease: A randomized controlled trial.Current journal of neurology · 2025
    Article
13. The gut-brain axis in early Parkinson's disease: from prodrome to prevention.Journal of neurology · 2025
    Review
14. The Impact of Diet on Parkinson's Disease: A Systematic Review.Cureus · 2024
    Review
15. The Effect of Gut Microbiota-Targeted Interventions on Neuroinflammation and Motor Function in Parkinson's Disease Animal Models-A Systematic Review.Current issues in molecular biology · 2024
    Review
16. Iron toxicity, ferroptosis and microbiota in Parkinson's disease: Implications for novel targets.Advances in neurotoxicology · 2024
    Article
17. The link between the gut microbiome, inflammation, and Parkinson's disease.Applied microbiology and biotechnology · 2023
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as